[Targeted therapy of urological tumours. Experimental field or established therapeutic approach?]

Area of Science:

• Oncology
• Urology
• Molecular Biology

Background:

• Conventional chemotherapy targets general cell replication, often causing significant side effects.
• Targeted therapies selectively inhibit molecular pathways driving cancer progression.
• While established for renal cell cancer, targeted therapy data for other urological tumors is limited.

Purpose of the Study:

• To review the current clinical efficacy and relevance of targeted therapeutic approaches in urological cancers.
• To evaluate the application of targeted therapies in prostate and bladder cancer treatment.
• To provide an overview of targeted therapy's role in diverse urological malignancies.

Main Methods:

• Literature review of clinical studies and research on targeted therapies in urological cancers.
• Analysis of data regarding targeted treatment efficacy in renal cell, prostate, and bladder cancers.
• Synthesis of current evidence on the role of molecular pathway inhibition in urological tumor treatment.

Main Results:

• Targeted therapies are a well-established treatment for metastatic renal cell cancer.
• Limited clinical data currently exists on the efficacy of targeted therapies for prostate and bladder cancers.
• Further research is needed to establish the role of targeted approaches in broader urological oncology.

Conclusions:

• Targeted therapies represent a significant advancement in cancer treatment by focusing on specific molecular drivers.
• The application of targeted therapies in urological cancers, particularly prostate and bladder, requires further investigation and clinical validation.
• Expanding the use of targeted approaches holds promise for improving outcomes in various urological malignancies.